Cannabinoid Receptor-Activating Compounds Killed Brain Cancer Cells in the Lab

Two fatty ethanolamides (FAA1 and FAA2) reduced C6 glioma cell viability, proliferation, and migratory potential in a dose-dependent manner. They triggered apoptotic cell death through mitochondrial integrity loss, likely by activating cannabinoid receptors and inhibiting the PI3K/Akt signaling pathway. Critically, neither compound was toxic to normal retinal glial cells.

In vitro study testing two fatty acid amides synthesized from andiroba oil (Carapa guianensis) on C6 glioma cells. Assessments included cell viability, proliferation, migration, mitochondrial membrane potential, and pathway analysis. Normal retinal glial cells were used as a toxicity control.

Gliomas are among the most aggressive and treatment-resistant brain cancers, with patients often surviving less than a year after diagnosis. Finding compounds that kill cancer cells while sparing normal cells is the central challenge, and these cannabinoid receptor-activating compounds showed that selectivity.

The endocannabinoid system has emerged as a target in cancer research. This study adds to the evidence that cannabinoid receptor activation can trigger cancer cell death through established oncological pathways (PI3K/Akt), connecting cannabis science to mainstream cancer biology.

In vitro study only; effects in living organisms may differ entirely. C6 glioma cells are a rat cell line and may not fully represent human glioblastoma. The compounds were derived from a specific natural product, and their pharmacokinetics in vivo are unknown.